AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24124709 — intervention group
Group type: EXPERIMENTAL
Intervention: ICP plus PbtO2 monitoring
Number of subjects: 46
Study 24124709 — intervention group
Group type: COMPARATOR
Intervention: ICP monitoring alone (Control)
Number of subjects: 46
Study 21132360 — intervention group
Group type: EXPERIMENTAL
Intervention: E (100 mg/m² i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m² i.v. d1 and 8, q28 days for 4 cycles)
Number of subjects: 1066
Study 21132360 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF followed by E
Number of subjects: 1066
Study 21132360 — intervention group
Group type: COMPARATOR
Intervention: E → CMF and CMF → E
Number of subjects: 1066
Study 21132360 — intervention group
Group type: COMPARATOR
Intervention: CMF → E
Number of subjects: 1066
Study 18166089 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable calcium phosphate bone cement (CPC)
Number of subjects: 30
Study 18166089 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 30
Study 18166089 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC-R group (CPC with no adverse reactions)
Number of subjects: 30
Study 16324851 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training at 30 degrees/s
Number of subjects: 55
Study 16324851 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training at 90 degrees/s
Number of subjects: 55
Study 16324851 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 55
Study 15162243 — intervention group
Group type: EXPERIMENTAL
Intervention: HT-EIH
Number of subjects: 29
Study 15162243 — intervention group
Group type: COMPARATOR
Intervention: HT-nEIH
Number of subjects: 29
Study 15162243 — intervention group
Group type: COMPARATOR
Intervention: UT
Number of subjects: 29
Study 11317536 — intervention group
Group type: EXPERIMENTAL
Intervention: Live tularemia vaccine
Number of subjects: 0
Study 9039083 — intervention group
Group type: EXPERIMENTAL
Intervention: Human brain natriuretic peptide-32 at a dose of 4 pmol/kg per minute
Number of subjects: 5
Study 9039083 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose infusion (control)
Number of subjects: 5
Study 8284070 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate 50 mg
Number of subjects: 254
Study 8284070 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate 100 mg
Number of subjects: 254
Study 8284070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 254
Study 8284070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 254
Study 8284070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 8284070 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate (multidose phase)
Number of subjects: 254
Study 8284070 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (multidose phase)
Number of subjects: 254
Study 3443139 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (n = 40, 1.5‐12.0 mg per day)
Number of subjects: 70
Study 3443139 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (n = 30, 30‐120 mg per day)
Number of subjects: 70
Study 3443139 — intervention group
Group type: COMPARATOR
Intervention: Switch from Propranolol to Prazosin
Number of subjects: 70
Study 31667680 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients
Number of subjects: 398
Study 31667680 — intervention group
Group type: COMPARATOR
Intervention: Internet users
Number of subjects: 398
Study 31667680 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 398
Study 30526548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS)
Number of subjects: 87
Study 30526548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound (LUS) with consolidation > 1 cm
Number of subjects: 87
Study 30526548 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR)
Number of subjects: 87
Study 30526548 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement between pediatrician and radiologist
Number of subjects: 87
Study 27564857 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored activity data provision to patients and clinicians with explicit goal setting
Number of subjects: 255
Study 27564857 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 255
Study 27564857 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored activity data provision to patients and clinicians
Number of subjects: 255
Study 25034127 — intervention group
Group type: EXPERIMENTAL
Intervention: allele-specific PCR (AS-PCR)
Number of subjects: 105
Study 25034127 — intervention group
Group type: EXPERIMENTAL
Intervention: ultra-deep pyrosequencing
Number of subjects: 105
Study 22764608 — intervention group
Group type: EXPERIMENTAL
Intervention: OVR simulation (galvanic vestibular stimulation)
Number of subjects: 21
Study 22764608 — intervention group
Group type: COMPARATOR
Intervention: Control (no OVR simulation)
Number of subjects: 21
Study 20559708 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m²) plus Cyclophosphamide (600 mg/m²) every 3 weeks (AC)
Number of subjects: 363
Study 20559708 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (50 mg/m²) plus Docetaxel (75 mg/m²) every 3 weeks (AD)
Number of subjects: 363
Study 20559708 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and Cyclophosphamide (AC)
Number of subjects: 363
Study 20559708 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin and Docetaxel (AD)
Number of subjects: 363
Study 18481035 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg l-amphetamine
Number of subjects: 19
Study 18481035 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg l-amphetamine
Number of subjects: 19
Study 18481035 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg l-amphetamine
Number of subjects: 19
Study 18481035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16162746 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (oral warfarin and low-molecular-weight heparin) plus prednisolone
Number of subjects: 56
Study 16162746 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone (non-anticoagulant group)
Number of subjects: 56
Study 16162746 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy (during acute exacerbation)
Number of subjects: 56
Study 12881333 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 48
Study 12881333 — intervention group
Group type: COMPARATOR
Intervention: Isopropyl unoprostone
Number of subjects: 48
Study 10208214 — intervention group
Group type: EXPERIMENTAL
Intervention: MIPuni
Number of subjects: 54
Study 10208214 — intervention group
Group type: COMPARATOR
Intervention: MIPbest
Number of subjects: 54
Study 7778637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (25 micrograms every 3 hours, max 8 doses)
Number of subjects: 276
Study 7778637 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone (0.5 mg every 6 hours, max 3 doses)
Number of subjects: 276
Study 7778637 — intervention group
Group type: COMPARATOR
Intervention: Intracervical dinoprostone
Number of subjects: 276
Study 7778637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol
Number of subjects: 276
Study 2803413 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 34
Study 2803413 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 34
Study 31877968 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazil nut oil (BNO), 10 mL daily for 30 days
Number of subjects: 31
Study 31877968 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil (SO), 10 mL daily for 30 days
Number of subjects: 31
Study 28573246 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Awareness Therapy (BAT)
Number of subjects: 60
Study 28573246 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercises
Number of subjects: 60
Study 28573246 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 26152421 — intervention group
Group type: EXPERIMENTAL
Intervention: Toltrazuril (15 mg/kg)
Number of subjects: 71
Study 26152421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR (50, 75, or 100 mg)
Number of subjects: 645
Study 23703422 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR (5, 10, or 15 mg)
Number of subjects: 645
Study 23703422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol IR
Number of subjects: 645
Study 23703422 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone IR
Number of subjects: 645
Study 21839452 — intervention group
Group type: EXPERIMENTAL
Intervention: Inside-out TO-TVT
Number of subjects: 224
Study 21839452 — intervention group
Group type: EXPERIMENTAL
Intervention: Outside-in TO-TVT
Number of subjects: 224
Study 18760637 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction followed by a structured rehabilitation program
Number of subjects: 58
Study 18760637 — intervention group
Group type: COMPARATOR
Intervention: Structured rehabilitation only
Number of subjects: 58
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking videos (12 videos containing cigarette smoking scenes)
Number of subjects: 20
Study 17725931 — intervention group
Group type: COMPARATOR
Intervention: Neutral videos (12 videos containing neutral scenes)
Number of subjects: 20
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported craving (0-100 scale) after smoking videos
Number of subjects: 20
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic skin response after smoking videos
Number of subjects: 20
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature after smoking videos
Number of subjects: 20
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure response after smoking videos
Number of subjects: 20
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin temperature response after smoking videos
Number of subjects: 20
Study 17725931 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses to videos of women smoking vs. men smoking
Number of subjects: 20
Study 15282383 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg natural vitamin E for 6 weeks
Number of subjects: 72
Study 15282383 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo for 6 weeks
Number of subjects: 72
Study 11317052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventilation techniques that avoid intubation and ventilation
Number of subjects: 0
Study 11317052 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies that maintain the lung open and minimize tidal volumes
Number of subjects: 0
Study 11317052 — intervention group
Group type: COMPARATOR
Intervention: Postnatal steroids
Number of subjects: 0
Study 9754590 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm exercise training (30 minutes of handgrip exercise four times a week for 4-6 weeks)
Number of subjects: 18
Study 9754590 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no intervention)
Number of subjects: 18
Study 7824863 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g lactulose ingestion in methane producers
Number of subjects: 14
Study 7824863 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g, 20 g, and 30 g lactulose ingestion
Number of subjects: 14
Study 7824863 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane producers
Number of subjects: 14
Study 7824863 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane and hydrogen excretion measurements
Number of subjects: 14
Study 3780236 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Creme
Number of subjects: 12
Study 3780236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynol II
Number of subjects: 12
Study 3780236 — intervention group
Group type: COMPARATOR
Intervention: Placebo jelly
Number of subjects: 12
Study 3780236 — intervention group
Group type: COMPARATOR
Intervention: Placebo creme
Number of subjects: 12
Study 30526031 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook Flexor™ sheath
Number of subjects: 95
Study 30526031 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific Navigator HD™ sheath
Number of subjects: 95
Study 30526031 — intervention group
Group type: COMPARATOR
Intervention: Both sheaths
Number of subjects: 95
Study 30526031 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjectively difficult sheath placement and longer time of placement
Number of subjects: 95
Study 29772084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 45
Study 29772084 — intervention group
Group type: COMPARATOR
Intervention: Entecavir (ETV)
Number of subjects: 45
Study 27285345 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic-resistance exercise therapy (3 weekly sessions of 60 minutes for 12 weeks)
Number of subjects: 43
Study 27285345 — intervention group
Group type: COMPARATOR
Intervention: No exercise control group
Number of subjects: 43
Study 24686284 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related motivation measures using handgrip force as a motivational measure.
Number of subjects: 0
Study 24686284 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic (satiety) and pharmacological manipulations.
Number of subjects: 0
Study 24686284 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay as a metric for reward goal values.
Number of subjects: 0
Study 22018769 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative depression care
Number of subjects: 2821
Study 20593498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + FOLFOX6 (arm A)
Number of subjects: 151
Study 20593498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab + FOLFIRI (arm B)
Number of subjects: 151
Study 20593498 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumors (arm A)
Number of subjects: 151
Study 20593498 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS wild-type tumors (arm B)
Number of subjects: 151
Study 20593498 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutated tumors (arm A)
Number of subjects: 151
Study 20593498 — intervention group
Group type: EXPERIMENTAL
Intervention: KRAS mutated tumors (arm B)
Number of subjects: 151
Study 18676556 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 0
Study 18676556 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% (placebo)
Number of subjects: 0
Study 18569647 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice Training (VT)
Number of subjects: 60
Study 18569647 — intervention group
Group type: COMPARATOR
Intervention: Voice Hygiene Lecture (VHL)
Number of subjects: 60
Study 18569647 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 15213045 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant free sterols
Number of subjects: 26
Study 15213045 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol esters
Number of subjects: 26
Study 15213045 — intervention group
Group type: COMPARATOR
Intervention: Control (low-fat milk-based beverage alone)
Number of subjects: 26
Study 11284816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 150
Study 11284816 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 150
Study 11284816 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 150
Study 11284816 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blocking drugs
Number of subjects: 150
Study 9393381 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 19
Study 9393381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9393381 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen use (observational studies)
Number of subjects: 19
Study 8144294 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk vitamin A per gram milk fat
Number of subjects: 0
Study 8144294 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk vitamin A concentration
Number of subjects: 0
Study 8144294 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum retinol concentration
Number of subjects: 0
Study 8144294 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk indicators
Number of subjects: 0
Study 8144294 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk vitamin A
Number of subjects: 0
Study 3611943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat clearance technique
Number of subjects: 20
Study 3611943 — intervention group
Group type: COMPARATOR
Intervention: Manual dissection method
Number of subjects: 20
Study 3611943 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 20
Study 31620815 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VMP
Number of subjects: 91
Study 31620815 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 91
Study 27694633 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 10 µg
Number of subjects: 128
Study 27694633 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 30 µg and alum adjuvant
Number of subjects: 128
Study 27694633 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 60 µg and alum adjuvant
Number of subjects: 128
Study 27694633 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine with 60 µg and nonadjuvant
Number of subjects: 128
Study 27694633 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-PreF vaccine (all dosages)
Number of subjects: 128
Study 27694633 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 128
Study 24409937 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous curvilinear capsulorhexis (CCC) using an irrigation‐aspiration system by a phaco machine in Group 1 (27 eyes)
Number of subjects: 50
Study 24409937 — intervention group
Group type: COMPARATOR
Intervention: CCC using an ocular visco‐elastic device (OVD) and utrata forceps in Group 2 (26 eyes)
Number of subjects: 50
Study 23165609 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (Ex)
Number of subjects: 351
Study 23165609 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (Iso: 165 mg/d)
Number of subjects: 351
Study 23165609 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise and isoflavone (ExIso)
Number of subjects: 351
Study 23165609 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 351
Study 21372654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 84
Study 21372654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg
Number of subjects: 84
Study 21372654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 19693532 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy runners
Number of subjects: 18
Study 19693532 — intervention group
Group type: COMPARATOR
Intervention: Illness-prone runners
Number of subjects: 18
Study 19693532 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 16887418 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelation therapy with edetate calcium disodium (EDTA) for 3 months and repeated therapy to maintain BLB below 20 microg
Number of subjects: 108
Study 16887418 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 108
Study 15251637 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin (CII) therapy
Number of subjects: 4864
Study 15251637 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia
Number of subjects: 4864
Study 11738907 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage soft contact lens (BSCL)
Number of subjects: 120
Study 11738907 — intervention group
Group type: COMPARATOR
Intervention: No bandage soft contact lens (no BSCL)
Number of subjects: 120
Study 11738907 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5%
Number of subjects: 120
Study 11738907 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren (diclofenac sodium 0.1%)
Number of subjects: 120
Study 9257204 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexor hallucis brevis
Number of subjects: 10
Study 9257204 — intervention group
Group type: COMPARATOR
Intervention: Adductor pollicis
Number of subjects: 10
Study 8300044 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 11
Study 3747484 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 52
Study 3747484 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus health education
Number of subjects: 52
Study 3747484 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study 29126078 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil massage (moderate pressure)
Number of subjects: 44
Study 29126078 — intervention group
Group type: COMPARATOR
Intervention: Routine NICU care (Control)
Number of subjects: 44
Study 27507007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 49
Study 24373823 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy with Na2B12H11SH (BSH)
Number of subjects: 0
Study 24373823 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy with p‐dihydroxyborylphenylalanine (BPA)
Number of subjects: 0
Study 24373823 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy with temozolomide
Number of subjects: 0
Study 23093273 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 9522
Study 23093273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9522
Study 20213817 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 51
Study 20213817 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral globus pallidus internus (GPi) deep brain stimulation (DBS)
Number of subjects: 51